Magnolol suppresses metastasis via inhibition of invasion, migration, and matrix metalloproteinase-2/-9 activities in PC-3 human prostate carcinoma cells

Bioscience, Biotechnology and Biochemistry

Volumn 74, Issue 5, 2010, Pages 961-967

  Hwang, Eun Sun ^a   Park, Kwang Kyun ^b  

^a Jeonju University   (South Korea)

^b Yonsei University College of Dentistry   (South Korea)

Author keywords

Invasion; Magnolol; Matrix metalloproteinase; Metastasis; Prostate cancer

Indexed keywords

ANTICANCER ACTIVITIES; ARACHIDONIC ACIDS; CANCER CELLS; CANCER INVASION; CELLULAR PROLIFERATIONS; COLORIMETRIC ASSAYS; CYCLOOXYGENASE 2; DOSE-DEPENDENT MANNER; GELATIN ZYMOGRAPHY; HUMAN PROSTATE; HUMAN PROSTATE CANCER CELLS; HYDROXYLATED BIPHENYLS; KEY ENZYMES; MAGNOLOL; MATRIX METALLOPROTEINASE-2; MATRIX METALLOPROTEINASES; MOLECULAR MECHANISM; MRNA LEVEL; PROSTATE CANCERS; STEM BARK; WESTERN BLOTS;

BLOOD VESSELS; CELL PROLIFERATION; ENZYME INHIBITION; ENZYMES; GROWTH KINETICS;

PATHOLOGY;

BIPHENYL DERIVATIVE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GELATINASE A; GELATINASE B; LIGNAN; MAGNOLOL;

ARTICLE; CANCER INVASION; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; METASTASIS; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

BIPHENYL COMPOUNDS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGNANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS;

MAGNOLIA OFFICINALIS;

EID: 77955375922     PISSN: 09168451     EISSN: 13476947     Source Type: Journal    
DOI: 10.1271/bbb.90785     Document Type: Article

References (42)

1. Ikarashi Y, Yuzurihara M, Sakakibara I, Nakai Y, Hattori N, and Maruyama Y, Planta Med., 67, 709-713 (2001).
2. Zhang WW, Li Y, Wang XQ, Tian F, Cao H, Wang MW, and Sun QS, World J. Gastroenterol., 11, 4414-4418 (2005).
3. Lee MM, Hseih MT, Kuo JS, Yeh FT, and Huang HM, Neuroreport, 9, 3451-3456 (1998).
4. Ho KY, Tsai CC, Chen CP, Huang JS, and Lin CC, Phytother. Res., 15, 139-141 (2001).
5. Fong W.-F., Tse AK, Poon K.-H., and Wang C, Int. J. Biochem. Cell Biol., 37, 427-441 (2005).
6. Lin SY, Chang YT, Liu JD, Yu CH, Ho YS, Lee YH, and Lee WS, Mol. Carcinol., 32, 73-83 (2001).
7. Lin SY, Liu JD, Chang HC, Yeh SD, Lin CH, and Lee WS, J. Cell. Biochem., 84, 532-544 (2002).
8. Lowe JF and Frazee LA, Pharmacother., 26, 353-359 (2006).
9. Coleman RE, Cancer Treat. Rev., 27, 165-176 (2001).
10. Hall CL, Kang S, Macdougald OA, and Keller ET, J. Cell. Biochem., 97, 661-672 (2006).
11. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, and De Marzo AM, Cancer Lett., 215, 1-20 (2004).
12. Warner TD and Mitchell JA, FASEB J., 18, 790-804 (2004).
13. Simmons DL, Botting RM, and Hla T, Pharmacol. Rev., 56, 387-437 (2004).
14. Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, Yoshimura N, Hla T, and Wada S, Cancer, 89, 589-596 (2000).
15. Ferrandez A, Prescott S, and Burt RW, Curr. Pharm. Des., 9, 2229-2251 (2003).
16. Rich TA and Shepard R, Am. J. Clin. Oncol., 26, S110-S113 (2003).
17. Hussain T, Gupata S, Adhami VM, and Mukhtar H, Int. J. Cancer, 113, 660-669 (2005).
18. Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, Huang M, Batra RK, and Dubinett SM, Cancer Res., 65, 5211-5220 (2005).
19. Tjandrawinata RR, Dahiya R, and Hughes-Fulford M, Br. J. Cancer, 75, 1111-1118 (1997).
20. Hughes-Fulford M, Chen Y, and Tjandrawinata RR, Carcinogenesis, 22, 701-707 (2001).
21. Nicolson GL, Biochem. Biophys. Acta, 948, 175-224 (1998).
22. Bajaj GK, Kleinberg L, and Terezakis S, Cancer Invest., 23, 363-376 (2005).
23. Liotta LA, Tryggvason K, Gabbisa S, Hart I, and Foltz CM, Nature, 284, 67-68 (1980).
24. Saikali Z and Singh G, Anticancer Drugs, 14, 773-778 (2003).
25. Leibovici D, Kamat AM, Pettaway CA, Pagliaro L, Rosser CJ, Logothetis C, and Pisters LL, J. Urol., 174, 2186-2190 (2005).
26. Bellon G, Martiny L, and Robinet A, Crit. Rev. Oncol. Hematol., 49, 203-220 (2004).
27. Minard ME, Kim LS, Price JE, and Gallick GE, Breast Cancer Res. Treat., 84, 21-32 (2004).
28. Valachovicova T, Slivova V, Bergman H, Shuherk J, and Sliva D, Int. J. Oncol., 25, 1389-1395 (2004).
29. Slivova V, Zaloga G, DeMichele SJ, Mukerji P, Huang YS, Siddiqui R, Harvey K, Valachovicova T, and Sliva D, Nutr. Cancer, 52, 66-73 (2005).
30. Hwang E and Lee HJ, Exp. Biol. Med., 231, 322-327 (2006).
31. Mook OR, Frederiks WM, and van Noorden CJ, Biochim. Biophys. Acta, 1705, 69-89 (2004).
32. Klein G, Vellenga E, Fraaije MW, Kamps WA, and de Bont ES, Crit. Rev. Oncol. Hematol., 50, 87-100 (2004).
33. Matchett MD, Mackinnon SL, Sweeney MI, Gottschall-Pass KT, and Hurta RA, J. Nutr. Biochem., 17, 117-125 (2006).
34. Roomi MW, Ivanov V, Netke S, Kalinovsky T, Niedzwiecki A, and Rath M, In Vivo, 20, 25-32 (2006).
35. Zucker S and Vacirca J, Cancer Metastasis Rev., 23, 101-117 (2004).
36. Yanagisawa N, Geironson L, Al-Soud WA, and Ljungh A, FEMS Immunol. Med. Microbiol., 44, 197-204 (2005).
37. Ikeda K and Nagase H, Biol. Pharm. Bull., 25, 1546-1549 (2002).
38. Yang SE, Hsieh MT, Tsai TH, and Hsu SL, Br. J. Pharmacol., 138, 193-201 (2003).
39. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, and Patierno SR, Cancer Res., 60, 4629-4637 (2000).
40. Xiong B, Sun TJ, Hu WD, Cheng FL, Mao M, and Zhou YF, World J. Gastroenterol., 11, 1105-1108 (2005).
41. Ikeda K, Sakai Y, and Nagase H, Phytother. Res., 17, 93-97 (2003).
42. Sun WH, Sun YL, Fang RN, Shao Y, Xu HC, Xue QP, Ding GX, and Cheng YL, Jpn. J. Clin. Oncol., 35, 707-713 (2005).